EUCTR2016-000603-91-IT进行中（未招募）1 期
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with N ivolumab (BMS-936558) in Subjects with Advanced Solid Tumors - ooo
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 235
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Men and women at least 18 years of age
- •- Advanced solid tumors
- •- Eastern Cooperative Oncology Group (ECOG) 0-1
- •- Acceptable lab testing results
- •- Allow biopsies
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 298
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 74
排除标准
- •- Central nervous system (CNS) tumors
- •- Uncontrolled or significant cardiovascular diseases
- •- Active or known autoimmune disease
- •- Organ transplant
研究者
相似试验
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2016-000603-91-DEBristol-Myers Squibb International Corporation246
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumaband/or Ipilimumab in Subjects With Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2015-004816-39-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO166
尚未招募
不适用
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in Subjects with Advanced Solid TumorsDuring the Dose Escalation phase the following tumor histologies permitted except primary CNS tumorsNL-OMON47099Bristol-Myers Squibb20
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors.EUCTR2015-004816-39-NLBristol-Myers Squibb International Corporation166
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 19.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2015-004816-39-ESBristol-Myers Squibb International Corporation245